Trastuzumab Not Yet Recruiting Phase 1 Trials for HER-2 protein overexpression / Tumors, Solid Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03680560Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers